Non-Executive Director Mike Harsh addresses Imagion Biosystems’ investors. November, 2019.
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited